Dihexa: FDA Status and Evidence
An experimental compound studied in animals for memory. It is not FDA-approved, has no compounding pathway, and has no controlled human-trial evidence.
Medically reviewed by Charles Kamen, MD, board-certified neurologist · ·
What the research shows
Dihexa is an angiotensin IV analog studied in animal and cell models of memory and synapse formation (McCoy, Journal of Pharmacology and Experimental Therapeutics, 2013). No controlled human trials have been published, so its safety and effect in people are unknown.
Frequently Asked Questions
Is Dihexa FDA-approved?
No. Dihexa has never been approved by FDA.
Can a pharmacy compound Dihexa?
Dihexa acetate was nominated for the 503A bulks list and the nomination was withdrawn. It is not on any current FDA bulk-substance list.
Has Dihexa been tested in humans?
No controlled human trials have been published. The evidence comes from animal and laboratory studies.
Selected Research
Peer-reviewed sources on Dihexa. Research does not constitute a treatment recommendation; appropriateness is determined only after a medical evaluation.
Related Cognitive & neurological support
Cerebrolysin
A neuropeptide preparation studied for cognition and neuro-recovery - supervised by a board-certified neurologist in Las Vegas.
P-21
A peptide studied for cognition and neurogenesis - supervised by a board-certified neurologist in Las Vegas.
DSIP (Delta Sleep-Inducing Peptide)
A peptide studied for sleep and stress regulation - supervised by a board-certified neurologist in Las Vegas.
Semax
A peptide studied for cognition and focus - supervised by a board-certified neurologist in Las Vegas.